Aclaris Therapeutics (STU:8AT) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8AT Aclaris Therapeutics Inc STU:8AT
33 GF Score
Price €5.11
GF Value €0.37
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Aclaris Therapeutics SpecialCharges?

Special Charges only applies to banks.

STU:8AT
33GF Score
Aclaris Therapeutics Inc STU:8AT
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aclaris Therapeutics (STU:8AT) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of €5.11 is trading 1279.7% above its estimated GF Value™ of €0.37. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:8AT:

  • SpecialCharges:
  • GF Value™: €0.37 vs. price of €5.11 (1279.7% above fair value)
  • GF Score™: 33/100 with 8 warning signs

No single metric tells the full story. See the STU:8AT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aclaris Therapeutics Business Description

Other Exchanges ACRS:USA0H8T:UK
Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
33GF Score

Get the complete analysis for STU:8AT

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.11
Price
€0.37
GF Value